$ABOS
Acumen Pharmaceuticals Inc Stock $abos

$abos Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000157688524000047 Filed on March 26, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.325M	$5.193M	$18.82M
YoY Change	20.42%	48.29%	46.16%
% of Gross Profit
Research & Development	$12.45M	$13.29M	$42.32M
YoY Change	42.88%	23.7%	30.77%
% of Gross Profit
Depreciation & Amortization	$16.00K	$21.00K	$61.00K
YoY Change	14.29%	75.0%	90.63%
% of Gross Profit
Operating Expenses	$17.77M	$18.49M	$61.14M
YoY Change	35.32%	29.74%	35.15%
Operating Profit	-$17.77M		-$61.14M
YoY Change	35.32%		35.15%
Interest Expense	$1.000M	$2.010M	$8.850M
YoY Change	-45.41%	44.4%	269.98%
% of Operating Profit
Other Income/Expense, Net	$2.901M	-$21.00K	-$83.00K
YoY Change	58.7%	110.0%	-103.49%
Pretax Income	-$14.87M	-$16.50M	-$52.37M
YoY Change	31.54%	28.22%	22.2%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$14.87M	-$16.50M	-$52.37M
YoY Change	31.54%	28.22%	22.2%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.25		-$1.08
Diluted Earnings Per Share	-$0.25	-$0.28	-$1.08
COMMON SHARES
Basic Shares Outstanding	60.08M shares	57.91M shares	48.61M shares
Diluted Shares Outstanding	59.81M shares		48.61M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$252.5M	$243.5M	$243.5M
YoY Change	79.84%	37.11%	37.11%
Cash & Equivalents	$46.93M	$66.89M	$66.89M
Short-Term Investments	$205.6M	$176.6M	$176.6M
Other Short-Term Assets	$395.0K	$3.093M	$3.093M
YoY Change	34.35%	1205.06%	13.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$255.8M	$246.6M	$246.6M
YoY Change	77.62%	36.76%	36.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$117.0K	$503.0K	$503.0K
YoY Change	-22.52%	204.85%	86.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$44.11M	$62.55M	$62.55M
YoY Change	1.59%	294.98%	294.98%
Other Assets	$324.0K	$454.0K	$454.0K
YoY Change	66.15%	200.66%	200.66%
Total Long-Term Assets	$45.14M	$63.51M	$63.51M
YoY Change	2.97%	290.64%	290.64%
TOTAL ASSETS
Total Short-Term Assets	$255.8M	$246.6M	$246.6M
Total Long-Term Assets	$45.14M	$63.51M	$63.51M
Total Assets	$301.0M	$310.1M	$310.1M
YoY Change	60.2%	57.75%	57.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.079M	$1.379M	$1.379M
YoY Change	304.07%	-15.91%	-15.91%
Accrued Expenses	$2.905M	$10.62M	$10.62M
YoY Change	-63.33%	75.86%	75.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$756.0K	$756.0K
YoY Change
Total Short-Term Liabilities	$8.472M	$12.97M	$12.97M
YoY Change	-3.5%	66.04%	66.04%
LONG-TERM LIABILITIES
Long-Term Debt	$30.21M	$29.90M	$29.90M
YoY Change
Other Long-Term Liabilities	$252.0K	$284.0K	$284.0K
YoY Change
Total Long-Term Liabilities	$30.46M	$30.18M	$30.18M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.472M	$12.97M	$12.97M
Total Long-Term Liabilities	$30.46M	$30.18M	$30.18M
Total Liabilities	$38.93M	$43.15M	$43.15M
YoY Change	343.48%	452.38%	452.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$237.7M	-$222.8M
YoY Change	30.82%	30.75%
Common Stock	$6.000K	$6.000K
YoY Change	50.0%	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$262.0M	$267.0M	$267.0M
YoY Change
Total Liabilities & Shareholders Equity	$301.0M	$310.1M	$310.1M
YoY Change	60.2%	57.75%	57.75%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$14.87M	-$16.50M	-$52.37M
YoY Change	31.54%	28.22%	22.2%
Depreciation, Depletion And Amortization	$16.00K	$21.00K	$61.00K
YoY Change	14.29%	75.0%	90.63%
Cash From Operating Activities	-$17.86M	-$8.314M	-$43.06M
YoY Change	75.52%	-25.79%	22.5%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$11.00K	$21.00K
YoY Change		-68.57%	-86.96%
Acquisitions
YoY Change
Other Investing Activities	-$9.192M	-$48.79M	-$171.7M
YoY Change	-78.08%	139.34%	-536.26%
Cash From Investing Activities	-$9.203M	-$48.81M	-$171.7M
YoY Change	-78.05%	139.04%	-538.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$122.2M
YoY Change			3123.34%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.107M	29.13M	151.8M
YoY Change		596.3%	3784.13%
NET CHANGE
Cash From Operating Activities	-$17.86M	-8.314M	-43.06M
Cash From Investing Activities	-$9.203M	-48.81M	-171.7M
Cash From Financing Activities	$7.107M	29.13M	151.8M
Net Change In Cash	-$19.96M	-27.99M	-62.98M
YoY Change	-61.7%	2.02%	-893.32%
FREE CASH FLOW
Cash From Operating Activities	-$17.86M	-$8.314M	-$43.06M
Capital Expenditures	$11.00K	$11.00K	$21.00K
Free Cash Flow	-$17.87M	-$8.325M	-$43.09M
YoY Change	75.63%	-25.92%	22.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40551
CY2023	dei	Entity Registrant Name EntityRegistrantName	Acumen Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	36-4108129
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	427 Park St.
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3093000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	62553000	usd
CY2023Q4	abos	Dues And Subscriptions Current DuesAndSubscriptionsCurrent	175000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1063000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51308000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43376000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001576885
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	134200000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	60079778	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66886000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130101000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	176636000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	47504000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2724000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	246615000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	180329000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15837000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	233000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	122000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	165000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	381000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	105000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	221000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	151000	usd
CY2023Q4	us-gaap	Assets Assets	310125000	usd
CY2022Q4	us-gaap	Assets Assets	196587000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1379000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1640000	usd
CY2023Q4	abos	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	4387000	usd
CY2022Q4	abos	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	2717000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3350000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	756000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	110000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	105000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12971000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7812000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	284000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	29897000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	43152000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7812000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57910461	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57910461	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41025062	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41025062	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	489453000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	359949000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222798000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170427000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	312000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-751000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	266973000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	188775000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310125000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	196587000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42318000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32361000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18820000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12876000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	61138000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	45237000	usd
CY2023	us-gaap	Interest Income Operating InterestIncomeOperating	10791000	usd
CY2022	us-gaap	Interest Income Operating InterestIncomeOperating	2392000	usd
CY2023	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-1360000	usd
CY2022	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
CY2023	us-gaap	Interest Expense InterestExpense	581000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-83000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8767000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2381000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52371000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-42856000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-520000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48609383	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48609383	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40601936	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40601936	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	225183000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3792000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-520000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3061000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-42856000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	188775000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	121904000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	325000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1132000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1063000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6145000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52371000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-52371000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-42856000	usd
CY2023	us-gaap	Depreciation Depreciation	61000	usd
CY2022	us-gaap	Depreciation Depreciation	32000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	6145000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3061000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3121000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-487000	usd
CY2023	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-1360000	usd
CY2022	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	0	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	123000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	137000	usd
CY2023	abos	Other Noncash Expense Research And Development OtherNoncashExpenseResearchAndDevelopment	739000	usd
CY2022	abos	Other Noncash Expense Research And Development OtherNoncashExpenseResearchAndDevelopment	0	usd
CY2023	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	11000	usd
CY2022	us-gaap	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments	0	usd
CY2023	abos	Other Noncash Expense Interest OtherNoncashExpenseInterest	145000	usd
CY2022	abos	Other Noncash Expense Interest OtherNoncashExpenseInterest	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	369000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1700000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	70000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	137000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-261000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	552000	usd
CY2023	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	1670000	usd
CY2022	abos	Increase Decrease In Accrued Clinical Trial Expenses IncreaseDecreaseInAccruedClinicalTrialExpenses	2570000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2989000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-562000	usd
CY2023	abos	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability	17000	usd
CY2022	abos	Increase Decrease In Finance Lease Liability IncreaseDecreaseInFinanceLeaseLiability	0	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-110000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-137000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43064000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35153000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	250634000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	41514000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	78981000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80860000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	21000	usd
CY2022	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	161000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-171671000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39185000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	121904000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3792000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	30000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	476000	usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	325000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	115000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	151753000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3907000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-62982000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	7939000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130101000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	122162000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67119000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130101000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	169000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	739000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	399000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	242000	usd
CY2023	abos	Noncash Issuance Of Warrant With Term Loan NoncashIssuanceOfWarrantWithTermLoan	1132000	usd
CY2022	abos	Noncash Issuance Of Warrant With Term Loan NoncashIssuanceOfWarrantWithTermLoan	0	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acumen Pharmaceuticals, Inc. (“Acumen” or the “Company”) was incorporated in 1996 in the state of Delaware. Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what the Company believes to be a key underlying cause of Alzheimer’s disease (“AD”). Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. The Company’s scientific founders pioneered research on soluble amyloid-beta oligomers (“AßOs”), which are globular assemblies of the amyloid-beta (“Aß”) peptide that are distinct from Aß monomers and amyloid plaques. Based on decades of research and supporting evidence, AßOs have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. The Company is currently focused on advancing a targeted immunotherapy drug candidate, sabirnetug, in clinical development following Phase 1 results in “early AD” patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology) that were reported in July 2023. Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (“IgG2”) monoclonal antibody (“mAb”) that was designed to selectively target </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.99pt;font-weight:400;line-height:120%">AßOs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, has demonstrated functional and protective effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic mouse models for AD.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the uncertainty of whether its intellectual property will develop into successful commercial products. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offering </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2023, the Company issued 16,774,193 shares of its common stock, $0.0001 par value per share (“Common Stock”), in a public offering (the “Offering”) at a price of $7.75 per share. The aggregate net proceeds from the Offering, after underwriting discounts and commissions and other offering expenses, were $121.9 million. See additional discussion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Stockholders’ Equity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December 31, 2023 and 2022, the Company had an accumulated deficit of $222.8 million and $170.4 million, respectively, and working capital of $233.6 million and $172.5 million, respectively. During 2023, the Company received cash from the Offering and borrowings with net proceeds of $29.5 million under a term loan facility (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6. Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Management believes that the Company has sufficient cash to continue operating activities for beyond 12 months from issuance of these financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future capital requirements will depend upon many factors, including the timing and extent of spending on research and development and market acceptance of the Company’s products, if approved for commercial sale. The Company expects that it will need to obtain additional financing to complete clinical trials and launch and commercialize any product candidates for which it receives regulatory approval. Until such time, if ever, as the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. There can be no assurance that any such financing will be available on terms acceptable to the Company, or at all. To the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation of other preferences that adversely affect the rights of common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting the Company’s ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. The Company may be required to delay, limit, reduce or terminate its product discovery and development activities or future commercialization efforts. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.99pt;font-weight:400;line-height:120%">The Company completed a Phase 1 clinical trial of sabirnetug in the second quarter of 2023, which the Company named “INTERCEPT-AD.” This trial enrolled 65 patients with “early AD” and 62 participants received at least one dose of study drug. INTERCEPT-AD was a U.S.-based, multi-center, randomized, double-blind, placebo-controlled clinical trial with overlapping single ascending dose and multiple ascending dose cohorts evaluating patients with early AD. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company announced topline results from INTERCEPT-AD, which demonstrated that sabirnetug met the primary and secondary objectives of this study in 62 participants with early AD</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.99pt;font-weight:400;line-height:120%">. The Company expects to initiate a Phase 2 clinical trial of sabirnetug called “ALTITUDE-AD” in the first half of 2024.</span></div>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-222800000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-170400000	usd
CY2023Q4	abos	Working Capital WorkingCapital	233600000	usd
CY2022Q4	abos	Working Capital WorkingCapital	172500000	usd
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	29500000	usd
CY2023Q2	abos	Number Of Patients Enrolled In Trial NumberOfPatientsEnrolledInTrial	65	patient
CY2023Q2	abos	Number Of Participants Enrolled In Trial With One Dose Of Study Drug Received NumberOfParticipantsEnrolledInTrialWithOneDoseOfStudyDrugReceived	62	participant
CY2023Q3	abos	Number Of Participants Enrolled In Trial With One Dose Of Study Drug Received With Primary And Secondary Objectives Met NumberOfParticipantsEnrolledInTrialWithOneDoseOfStudyDrugReceivedWithPrimaryAndSecondaryObjectivesMet	62	participant
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting periods. These estimates and assumptions are based on the Company’s historical experience, and on various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. </span></div>Actual results may differ from these estimates under different assumptions or conditions. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. The more significant estimates and assumptions by management include, among others: the valuation allowance of deferred tax assets resulting from net operating losses, the valuation of stock options, the valuation of the warrant to purchase Common Stock and the valuation of embedded derivatives within the Company’s debt, long-term.
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	66200000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	129100000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66886000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130101000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	233000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67119000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130101000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s cash and cash equivalents are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses due to credit risk on such accounts during any of the periods presented.</span></div>
CY2023	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Embedded Derivatives</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates embedded derivatives within debt to determine whether the embedded derivatives should be bifurcated from the host instrument and accounted for as a derivative at fair value that will be remeasured at each reporting period for the term of the loan, with changes in fair value recorded in the statements of operations and comprehensive loss. Management initially assesses the probability of the occurrence of trigger events for bifurcated embedded derivatives in determining fair value. The probability is reassessed at each reporting period during the term of a loan.</span></div>
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9571358	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5610893	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	176654000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	179000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	197000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	176636000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	62225000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	343000	usd
CY2023Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	15000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	62553000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	238879000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	522000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	212000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	239189000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	48212000	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent	0	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Current DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent	708000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	47504000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	15880000	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	0	usd
CY2022Q4	abos	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Noncurrent DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	43000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	15837000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	64092000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	751000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	63341000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	84580000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	158000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	12074000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	54000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	96654000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	212000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	32541000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	65000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	30800000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	686000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	63341000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	751000	usd
CY2023	abos	Debt Securities Available For Sale Noncurrent Term DebtSecuritiesAvailableForSaleNoncurrentTerm	P2Y
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	192441000	usd
CY2023Q4	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	1680000	usd
CY2022Q4	abos	Research And Development Service Agreements Current ResearchAndDevelopmentServiceAgreementsCurrent	1077000	usd
CY2023Q4	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	807000	usd
CY2022Q4	abos	Prepaid Insurance Current PrepaidInsuranceCurrent	1106000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	225000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	0	usd
CY2022Q4	abos	Dues And Subscriptions Current DuesAndSubscriptionsCurrent	105000	usd
CY2023Q4	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	98000	usd
CY2022Q4	abos	Prepaid Raw Materials Current PrepaidRawMaterialsCurrent	199000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	108000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3093000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3692000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2008000	usd
CY2023Q4	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	2186000	usd
CY2022Q4	abos	Research And Development Liability Current ResearchAndDevelopmentLiabilityCurrent	1211000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	249000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	212000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	131000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3350000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	17000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
CY2023	abos	Finance Lease Expense FinanceLeaseExpense	17000	usd
CY2022	abos	Finance Lease Expense FinanceLeaseExpense	0	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	133000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	154000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	5000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	43000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	128000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	111000	usd
CY2023	abos	Short Term Lease Rent Expense ShortTermLeaseRentExpense	15000	usd
CY2022	abos	Short Term Lease Rent Expense ShortTermLeaseRentExpense	13000	usd
CY2023	us-gaap	Lease Cost LeaseCost	160000	usd
CY2022	us-gaap	Lease Cost LeaseCost	124000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	17000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	121000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	154000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	739000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	399000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	242000	usd
CY2023Q4	abos	Noncash Research And Development Expense Finance Lease Right Of Use Assets NoncashResearchAndDevelopmentExpenseFinanceLeaseRightOfUseAssets	739000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.38
CY2022Q4	abos	Noncash Research And Development Expense Finance Lease Right Of Use Assets NoncashResearchAndDevelopmentExpenseFinanceLeaseRightOfUseAssets	0	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M12D
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.097
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.097
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	763000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	763000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	756000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	143000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	155000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	158000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	456000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	63000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	393000	usd
CY2023Q4	abos	Common Stock And Preferred Stock Shares Authorized CommonStockAndPreferredStockSharesAuthorized	310000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	abos	Common Stock Number Of Voting Rights CommonStockNumberOfVotingRights	1	votingright
CY2022Q3	abos	Sale Of Stock Commission Rate To Sales Agents SaleOfStockCommissionRateToSalesAgents	0.030
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6145000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3061000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.79
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5610893	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.36
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2045000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.76
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	111206	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14489	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.88
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	6251	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.33
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7523947	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.01
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9004000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4021147	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.17
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	7055000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	12300000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.027
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.005
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.011
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.225
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.221
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16555000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	13125000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	13328000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6788000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1849000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	675000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1381000	usd
CY2023Q4	abos	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	441000	usd
CY2022Q4	abos	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	0	usd
CY2023Q4	abos	Deferred Tax Assets Accruals And Other Temporary Differences DeferredTaxAssetsAccrualsAndOtherTemporaryDifferences	575000	usd
CY2022Q4	abos	Deferred Tax Assets Accruals And Other Temporary Differences DeferredTaxAssetsAccrualsAndOtherTemporaryDifferences	179000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34098000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22148000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	33661000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22118000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	437000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	30000	usd
CY2023Q4	abos	Deferred Tax Liabilities Embedded Debt Derivative Liabilities DeferredTaxLiabilitiesEmbeddedDebtDerivativeLiabilities	274000	usd
CY2022Q4	abos	Deferred Tax Liabilities Embedded Debt Derivative Liabilities DeferredTaxLiabilitiesEmbeddedDebtDerivativeLiabilities	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	163000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	30000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	437000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	30000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd

Files In Submission

Name	View Source	Status
0001576885-24-000047-index-headers.html	Edgar Link	pending
0001576885-24-000047-index.html	Edgar Link	pending
0001576885-24-000047.txt	Edgar Link	pending
0001576885-24-000047-xbrl.zip	Edgar Link	pending
a143151824_1acumenex1013.htm	Edgar Link	pending
a143151824_1acumenex1013001.jpg	Edgar Link	pending
a143151824_1acumenex1013002.jpg	Edgar Link	pending
a143151824_1acumenex1013003.jpg	Edgar Link	pending
a143151824_1acumenex1013004.jpg	Edgar Link	pending
a143151824_1acumenex1013005.jpg	Edgar Link	pending
a143151824_1acumenex1013006.jpg	Edgar Link	pending
a143151824_1acumenex1013007.jpg	Edgar Link	pending
a143151824_1acumenex1013008.jpg	Edgar Link	pending
a143151824_1acumenex1013009.jpg	Edgar Link	pending
a143151824_1acumenex1013010.jpg	Edgar Link	pending
a143151824_1acumenex1013011.jpg	Edgar Link	pending
a143151824_1acumenex1013012.jpg	Edgar Link	pending
a143151824_1acumenex1013013.jpg	Edgar Link	pending
a143151824_1acumenex1013014.jpg	Edgar Link	pending
a143151824_1acumenex1013015.jpg	Edgar Link	pending
a143151824_1acumenex1013016.jpg	Edgar Link	pending
a143151824_1acumenex1013017.jpg	Edgar Link	pending
a143151824_1acumenex1013018.jpg	Edgar Link	pending
a143151824_1acumenex1013019.jpg	Edgar Link	pending
a143151824_1acumenex1013020.jpg	Edgar Link	pending
a143151824_1acumenex1013021.jpg	Edgar Link	pending
a143151824_1acumenex1013022.jpg	Edgar Link	pending
a143151824_1acumenex1013023.jpg	Edgar Link	pending
a143151824_1acumenex1013024.jpg	Edgar Link	pending
a143151824_1acumenex1013025.jpg	Edgar Link	pending
a143151824_1acumenex1013026.jpg	Edgar Link	pending
a143151824_1acumenex1013027.jpg	Edgar Link	pending
a143151824_1acumenex1013028.jpg	Edgar Link	pending
a143151824_1acumenex1013029.jpg	Edgar Link	pending
a143151824_1acumenex1013030.jpg	Edgar Link	pending
a143151824_1acumenex1013031.jpg	Edgar Link	pending
a143151824_1acumenex1013032.jpg	Edgar Link	pending
a143151824_1acumenex1013033.jpg	Edgar Link	pending
a143151824_1acumenex1013034.jpg	Edgar Link	pending
a143151824_1acumenex1013035.jpg	Edgar Link	pending
a143151824_1acumenex1013036.jpg	Edgar Link	pending
a143151824_1acumenex1013037.jpg	Edgar Link	pending
a143151824_1acumenex1013038.jpg	Edgar Link	pending
a143151824_1acumenex1013039.jpg	Edgar Link	pending
a143151824_1acumenex1013040.jpg	Edgar Link	pending
a143151824_1acumenex1013041.jpg	Edgar Link	pending
a143151824_1acumenex1013042.jpg	Edgar Link	pending
a143151824_1acumenex1013043.jpg	Edgar Link	pending
abos-20231231.htm	Edgar Link	pending
abos-20231231.xsd	Edgar Link	pending
abos-20231231xexx311.htm	Edgar Link	pending
abos-20231231xexx312.htm	Edgar Link	pending
abos-20231231xexx321.htm	Edgar Link	pending
abos-20231231xexx322.htm	Edgar Link	pending
abos-20231231_g1.jpg	Edgar Link	pending
abos-20231231_g10.jpg	Edgar Link	pending
abos-20231231_g11.jpg	Edgar Link	pending
abos-20231231_g12.jpg	Edgar Link	pending
abos-20231231_g13.jpg	Edgar Link	pending
abos-20231231_g14.jpg	Edgar Link	pending
abos-20231231_g15.jpg	Edgar Link	pending
abos-20231231_g2.jpg	Edgar Link	pending
abos-20231231_g3.jpg	Edgar Link	pending
abos-20231231_g4.jpg	Edgar Link	pending
abos-20231231_g5.jpg	Edgar Link	pending
abos-20231231_g6.jpg	Edgar Link	pending
abos-20231231_g7.jpg	Edgar Link	pending
abos-20231231_g8.jpg	Edgar Link	pending
abos-20231231_g9.jpg	Edgar Link	pending
active_143152077x1xacume.htm	Edgar Link	pending
active_143152077x1xacume001.jpg	Edgar Link	pending
active_143152077x1xacume002.jpg	Edgar Link	pending
active_143152077x1xacume003.jpg	Edgar Link	pending
active_143152077x1xacume004.jpg	Edgar Link	pending
active_143152077x1xacume005.jpg	Edgar Link	pending
active_143152077x1xacume006.jpg	Edgar Link	pending
active_143152077x1xacume007.jpg	Edgar Link	pending
active_143152077x1xacume008.jpg	Edgar Link	pending
active_143152077x1xacume009.jpg	Edgar Link	pending
active_143152077x1xacume010.jpg	Edgar Link	pending
active_143152077x1xacume011.jpg	Edgar Link	pending
active_143152077x1xacume012.jpg	Edgar Link	pending
active_143152077x1xacume013.jpg	Edgar Link	pending
active_143152077x1xacume014.jpg	Edgar Link	pending
active_143152077x1xacume015.jpg	Edgar Link	pending
active_143152077x1xacume016.jpg	Edgar Link	pending
active_143152077x1xacume017.jpg	Edgar Link	pending
active_143152077x1xacume018.jpg	Edgar Link	pending
active_143152077x1xacume019.jpg	Edgar Link	pending
active_143152077x1xacume020.jpg	Edgar Link	pending
active_143152077x1xacume021.jpg	Edgar Link	pending
active_143152077x1xacume022.jpg	Edgar Link	pending
active_143152077x1xacume023.jpg	Edgar Link	pending
active_143152077x1xacume024.jpg	Edgar Link	pending
active_143152077x1xacume025.jpg	Edgar Link	pending
active_143152077x1xacume026.jpg	Edgar Link	pending
abos-20231231_def.xml	Edgar Link	unprocessable
abos-20231231_pre.xml	Edgar Link	unprocessable
abos-20231231_lab.xml	Edgar Link	unprocessable
abos-20231231_htm.xml	Edgar Link	completed
active_143152077x1xacume027.jpg	Edgar Link	pending
active_143152077x1xacume028.jpg	Edgar Link	pending
active_143152077x1xacume029.jpg	Edgar Link	pending
active_143152077x1xacume030.jpg	Edgar Link	pending
active_143152077x1xacume031.jpg	Edgar Link	pending
active_143152077x1xacume032.jpg	Edgar Link	pending
active_143152077x1xacume033.jpg	Edgar Link	pending
active_143152077x1xacume034.jpg	Edgar Link	pending
active_143152077x1xacume035.jpg	Edgar Link	pending
active_143152077x1xacume036.jpg	Edgar Link	pending
active_143152077x1xacume037.jpg	Edgar Link	pending
active_143152077x1xacume038.jpg	Edgar Link	pending
active_143152077x1xacume039.jpg	Edgar Link	pending
active_143152077x1xacume040.jpg	Edgar Link	pending
active_143152077x1xacume041.jpg	Edgar Link	pending
active_143152077x1xacume042.jpg	Edgar Link	pending
active_143152077x1xacume043.jpg	Edgar Link	pending
active_143152077x1xacume044.jpg	Edgar Link	pending
active_143152077x1xacume045.jpg	Edgar Link	pending
active_143152077x1xacume046.jpg	Edgar Link	pending
active_143152077x1xacume047.jpg	Edgar Link	pending
active_143152077x1xacume048.jpg	Edgar Link	pending
active_143152077x1xacume049.jpg	Edgar Link	pending
acumen-compensationrecoupm.htm	Edgar Link	pending
acumenex1014xhalozymeagr.htm	Edgar Link	pending
acumenex1014xhalozymeagr001.jpg	Edgar Link	pending
acumenex1014xhalozymeagr002.jpg	Edgar Link	pending
acumenex1014xhalozymeagr003.jpg	Edgar Link	pending
acumenex1014xhalozymeagr004.jpg	Edgar Link	pending
acumenex1014xhalozymeagr005.jpg	Edgar Link	pending
acumenex1014xhalozymeagr006.jpg	Edgar Link	pending
acumenex1014xhalozymeagr007.jpg	Edgar Link	pending
acumenex1014xhalozymeagr008.jpg	Edgar Link	pending
acumenex1014xhalozymeagr009.jpg	Edgar Link	pending
acumenex1014xhalozymeagr010.jpg	Edgar Link	pending
acumenex1014xhalozymeagr011.jpg	Edgar Link	pending
acumenex1014xhalozymeagr012.jpg	Edgar Link	pending
acumenex1014xhalozymeagr013.jpg	Edgar Link	pending
acumenex1014xhalozymeagr014.jpg	Edgar Link	pending
acumenex1014xhalozymeagr015.jpg	Edgar Link	pending
acumenex1014xhalozymeagr016.jpg	Edgar Link	pending
acumenex1014xhalozymeagr017.jpg	Edgar Link	pending
acumenex1014xhalozymeagr018.jpg	Edgar Link	pending
acumenex1014xhalozymeagr019.jpg	Edgar Link	pending
acumenex1014xhalozymeagr020.jpg	Edgar Link	pending
acumenex1014xhalozymeagr021.jpg	Edgar Link	pending
acumenex1014xhalozymeagr022.jpg	Edgar Link	pending
acumenex1014xhalozymeagr023.jpg	Edgar Link	pending
acumenex1014xhalozymeagr024.jpg	Edgar Link	pending
acumenex1014xhalozymeagr025.jpg	Edgar Link	pending
acumenex1014xhalozymeagr026.jpg	Edgar Link	pending
acumenex1014xhalozymeagr027.jpg	Edgar Link	pending
acumenex1014xhalozymeagr028.jpg	Edgar Link	pending
acumenex1014xhalozymeagr029.jpg	Edgar Link	pending
acumenex1014xhalozymeagr030.jpg	Edgar Link	pending
acumenex1014xhalozymeagr031.jpg	Edgar Link	pending
acumenex1014xhalozymeagr032.jpg	Edgar Link	pending
acumenex1014xhalozymeagr033.jpg	Edgar Link	pending
acumenex1014xhalozymeagr034.jpg	Edgar Link	pending
acumenex1014xhalozymeagr035.jpg	Edgar Link	pending
acumenex1014xhalozymeagr036.jpg	Edgar Link	pending
acumenex1014xhalozymeagr037.jpg	Edgar Link	pending
acumenex1014xhalozymeagr038.jpg	Edgar Link	pending
acumenex1014xhalozymeagr039.jpg	Edgar Link	pending
acumenex1014xhalozymeagr040.jpg	Edgar Link	pending
acumenex1014xhalozymeagr041.jpg	Edgar Link	pending
acumenex1014xhalozymeagr042.jpg	Edgar Link	pending
acumenex1014xhalozymeagr043.jpg	Edgar Link	pending
acumenex1014xhalozymeagr044.jpg	Edgar Link	pending
acumenex1014xhalozymeagr045.jpg	Edgar Link	pending
acumenex1014xhalozymeagr046.jpg	Edgar Link	pending
acumenex1014xhalozymeagr047.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rprt05-acumen10xkconsent.htm	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
abos-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABOS
Acumen Pharmaceuticals Inc Stock $abos

2024 Q1 Form 10-K Financial Statement

#000157688524000047 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS Acumen Pharmaceuticals Inc Stock $abos

2024 Q1 Form 10-K Financial Statement

#000157688524000047 Filed on March 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABOS
Acumen Pharmaceuticals Inc Stock $abos